Finance Support and Strategy for Life Science Companies. Finance is in our DNA; life science and healthcare technology are where we specialize. From strategic CFO advisory to operational accounting, we provide the financial leadership and backbone to companies from inception through exit. Our team is custom-built to serve yours. We design and implement financial infrastructure and manage the day-to-day financial and accounting operations. We advise and prepare for every step of transaction execution.

Our oral mTORC1 activator, NV-5138, is advancing into clinical studies for Treatment-Resistant Depression in the first half of 2018. Navitor to Develop NV-5138, an mTORC1 Inhibitor for Treatment Resistant Depression. Navitor targets nutrient sensors to unlock the potential of mTORC1 for a range of innovative medicines.

Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising function and ultimately leading to organ failure.

How to Improve Your Pinterest Marketing with IFTTT. Pinterest is now available to link to the online app IFTTT. Why This Business Left Its 10,000 Facebook Fans. Is Hootsuite or Buffer Better for Social Media Management? Sign up f.

A new class of targeted and programmable therapeutics developed using our Medicinal Nanoengineering. Accurins are nanoparticles designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease, enhancing efficacy while minimizing adverse effects on healthy tissues. We are developing our own pipeline.

Mitobridge is discovering and developing novel small molecule therapeutics that improve mitochondrial functions. The Company is building upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies to identify innovative approaches to medical treatment.

Benefits of Miniaturized Biologic Drug Conjugates. Pentarins effectively penetrate into solid tumors and kill cancer cells with highly selective binding to target proteins on or in tumor cells where they accumulate and hold a potent payload in the cell, leading to tumor cell death. PEN-221 is being developed to treat patients with neuroendocrine cancers including small cell lung cancer.